Jilin Province Huinan Changlong Bio-pharmacy (8049) announced a subscription of a structured deposit product from Industrial and Commercial Bank of China on 3 February 2026, with a principal amount of RMB100 million. The product offers a principal-guaranteed investment with a floating return, has a one-year term, a low internal risk rating, and an expected annualized return of approximately 2%. There is no option for early termination or redemption.

According to the announcement, the subscription is classified as a discloseable transaction under Chapter 19 of the GEM Listing Rules because at least one of the applicable percentage ratios, when considered on an aggregated basis, exceeds 5% but is less than 25%. As a result, it is subject to reporting and announcement requirements but does not require shareholder approval.

The Company stated that the purpose of the subscription is to manage surplus cash for higher returns compared to standard bank deposits while maintaining liquidity and low risk exposure. The transaction was funded by surplus cash and has not resulted in any reported losses as of the date of the announcement, and the Company affirmed that its working capital and operations remain unaffected.